Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer



Status:Recruiting
Conditions:Endocrine
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:18 - Any
Updated:1/20/2019
Start Date:May 4, 2015
End Date:August 1, 2020

Use our guide to learn which trials are right for you!

Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers

This randomized phase II trial studies how well iodine I-131 works with or without
selumetinib in treating patients with thyroid cancer that has returned or has spread from
where it started to other places in the body. Many thyroid cancers absorb iodine. Due to
this, doctors often give radioactive iodine (iodine I-131) alone to treat thyroid cancer as
part of standard practice. It is thought that the more thyroid tumors are able to absorb
radioactive iodine, the more likely it is that the radioactive iodine will cause those tumors
to shrink. Selumetinib may help radioactive iodine work better in patients whose tumors still
absorb radioactive iodine. It is not yet known whether iodine I-131 is more effective with or
without selumetinib in treating thyroid cancer.

PRIMARY OBJECTIVES:

I. To determine the response rate at 6 months following treatment with 131I (iodine I-131) in
combination with placebo or selumetinib for radioactive iodine-avid (RAIA) recurrent and/or
metastatic thyroid cancer.

SECONDARY OBJECTIVES:

I. To determine the best overall response following treatment with 131I in combination with
placebo or selumetinib for RAIA recurrent and/or metastatic thyroid cancer.

II. To compare the progression-free survival of patients with RAIA recurrent and/or
metastatic thyroid cancer treated with 131I in combination with placebo or selumetinib.

III. To compare serum thyroglobulin changes for patients with RAIA recurrent and/or
metastatic thyroid cancer treated with 131I in combination with placebo or selumetinib.

IV. To evaluate the safety and tolerability of 131I in combination with placebo or
selumetinib for patients with RAI-avid recurrent and/or metastatic thyroid cancer.

TERTIARY OBJECTIVES:

I. To explore the genomic and transcriptomic landscape of RAIA tumors for signatures that
correlate to therapeutic benefit achieved with 131I in combination with placebo or
selumetinib.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive selumetinib orally (PO) twice daily (BID) starting on week 1, day 1
and continuing through 2 days after iodine I-131 therapy has been administered. Approximately
3 weeks after beginning treatment with selumetinib, patients receive iodine I-131 PO.

ARM II: Patients receive placebo PO BID starting on week 1, day 1 and continuing through 2
days after iodine I-131 therapy has been administered. Approximately 3 weeks after beginning
treatment with placebo, patients receive iodine I-131 PO.

After completion of study treatment, patients are followed up at 1 and 3 months, every 3
months for 12 months, and then every 6 months for 2 years.

Inclusion Criteria:

- Diagnosis of recurrent and/or metastatic thyroid cancer

- Histological or cytological confirmation of thyroid carcinoma of follicular origin
(including papillary, follicular, or poorly differentiated subtypes and their
respective variants); NOTE: medullary and anaplastic thyroid cancers are excluded;
Hurthle cell carcinomas are excluded (defined as having an invasive tumor composed of
> 75% oncocytic [Hurthle] cells lacking the nuclear features of papillary carcinoma,
tumor necrosis, and marked mitotic activity); patients with oncocytic (Hurthle cell)
variants of papillary thyroid carcinoma (defined as a tumor composed of a majority of
oncocytic [Hurthle] cells having the nuclear features of papillary carcinoma) are
eligible to participate

- RAI-avid lesion on a radioiodine scan (a diagnostic, post-therapy, or post-ablation
scans) performed =< 24 months prior to registration, which suggests that therapy with
131I is justifiable in the judgment of the investigator

- Clinically or radiographically evident structural disease; patients with measurable
disease and those with only non-measurable (?non-target?) structural disease
(according to modified Response Evaluation Criteria in Solid Tumors [RECIST] version
[v] 1.1 criteria) are eligible;

NOTE 1: Modification of the RECIST v1.1 measurable disease criteria includes a change in
the definition of what is considered a measurable malignant lymph node; a malignant lymph
node is considered measurable if any of the following apply:

- It is noted to be RAI-avid on radioactive iodine imaging (diagnostic or post-therapy
whole body scans acceptable) and it measures >= 1 cm in the long axis,

- It is pathologically proven to be involved with thyroid cancer (by cytology or
pathology) and it measures >= 1 cm in the long axis, or

- Its short axis is >= 1.5 cm when assessed by computed tomography (CT) scan NOTE 2:
Patients only with biochemical evidence of disease without structural evidence of
cancer are not eligible for this study

- For patients with non-measurable, structural disease the following must apply:

- Undetectable thyroglobulin antibody AND

- A serum thyroglobulin of 10 ng/ml or greater in the context of suppressed
thyroid-stimulating hormone (TSH) (TSH =< 0.4 mcU/ml) =< 28 days prior to study
registration; use of any thyroglobulin assay is allowed, though all serum
thyroglobulin measurements for study purposes must be conducted with the same
thyroglobulin assay

- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2

- Able to swallow and retain orally-administered medication with no clinically
significant gastrointestinal abnormalities that may alter absorption

- Absolute neutrophil count (ANC) >= 1500/mm^3 (obtained =< 28 days prior to
randomization)

- Platelet count >= 100,000/mm^3 (obtained =< 28 days prior to randomization)

- Hemoglobin > 9.0 g/dL (obtained =< 28 days prior to randomization)

- Total bilirubin =< 1.5 x upper limit of normal (ULN) (obtained =< 28 days prior
to randomization)

- Aspartate transaminase (AST) =< 2.5 x ULN (or =< 5 x ULN in presence of liver
metastases) (obtained =< 28 days prior to randomization)

- Creatinine =< 1.5 mg/dL OR calculated creatinine clearance of >= 50 ml/min by
either the Cockcroft-Gault formula or 24-hours urine collection analysis
(obtained =< 28 days prior to randomization)

- Negative pregnancy test performed =< 7 days prior to registration for women of
childbearing potential only

- Provide informed written consent

- Willing to return to enrolling institution for follow-up (during the Active
Monitoring Phase of the study)

- Note: during the Active Monitoring Phase of a study (i.e., active treatment and
observation), participants must be willing to return to the consenting institution for
follow-up

- Willing to provide mandatory archival tumor tissue (block or minimum of 30
unstained slides from a primary or recurrent/metastatic thyroid cancer) for
correlative research purposes; NOTE: patients with less archival tumor tissue
available may still be eligible for the study after discussion with Academic and
Community Cancer Research United (ACCRU); receipt of archival tumor tissue is not
required for study registration and initiation of therapy

- Willing to provide mandatory blood samples for correlative research purposes

Exclusion Criteria:

- 131I therapy =< 6 months prior to registration; Note: 131I administered solely for
diagnostic purposes is not considered 131I therapy

- External beam radiation therapy =< 28 days prior to registration; note: previous
treatment with radiation is allowed if the investigator judges it will not compromise
patient safety on the study

- Having been treated with a total cumulative (lifetime) 131I therapeutic activity > 800
mCi (excluding 131I activity administered for diagnostic scans)

- Treatment with chemotherapy or targeted therapy (e.g. tyrosine kinase inhibitor) =< 28
days prior to registration

- Prior exposure to mitogen-activated protein kinase kinase (MEK), RAS, or RAF
inhibitors (note: previous exposure to sorafenib is allowed) OR history of
hypersensitivity to selumetinib, thyrotropin alpha (Thyrogen), or any excipient agents

- Unresolved toxicity > Common Terminology Criteria for Adverse Events (CTCAE) grade 2
from previous anti-cancer therapy, except for alopecia

- Cardiac conditions as follows:

- Uncontrolled hypertension (blood pressure [BP] >=150/95 mmHg despite medical
therapy)

- Left ventricular ejection fraction < 55% measured by echocardiography

- Atrial fibrillation with a ventricular rate > 100 beats per minute (bpm) on
electrocardiogram (ECG) at rest

- Symptomatic heart failure (New York Heart Association [NYHA] grade II-IV)

- Prior or current cardiomyopathy

- Severe valvular heart disease

- Uncontrolled angina (Canadian Cardiovascular Society grade II-IV despite medical
therapy)

- Acute coronary syndrome =< 6 months prior to registration

- Ophthalmological conditions as follows:

- Intra-ocular pressure > 21 mmHg, or uncontrolled glaucoma (irrespective of
intra-ocular pressure)

- Current or past history of central serous retinopathy or retinal vein occlusion

- Symptomatic or untreated leptomeningeal disease, brain metastasis, or spinal cord
compression

- Unable to follow a low iodine diet or requiring medication with high content in iodide
(e.g., amiodarone)

- Received iodinated intravenous contrast within =< 2 months of registration; avoidance
of iodinated oral contrast is also preferred but not strictly required for study
enrollment; NOTE: those who have had iodinated intravenous contrast within this time
frame may still be eligible if a urinary iodine analysis reveals that excess iodine
has been cleared (defined as urinary iodine documented to be < 300 mcg/day by either a
spot urinary iodine or 24-hour urinary iodine measurement)

- Any of the following:

- Pregnant women

- Nursing women

- Men or women of childbearing potential who are unwilling to employ adequate
contraception

- Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment
of the investigator, would make the patient inappropriate for entry into this study or
interfere significantly with the proper assessment of safety and toxicity of the
prescribed regimens

- Immunocompromised patients and patients known to be human immunodeficiency virus (HIV)
positive and currently receiving antiretroviral therapy; NOTE: patients known to be
HIV positive, but without clinical evidence of an immunocompromised state, are
eligible for this trial

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, hepatitis B infection, hepatitis C infection, symptomatic congestive heart
failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social
situations that would limit compliance with study requirements

- Receiving any other investigational agent which would be considered as a treatment for
the primary neoplasm

- Other active malignancy =< 2 years prior to registration that will interfere with
conduct of this trial; EXCEPTIONS: non-melanotic skin cancer or carcinoma-in-situ of
the cervix; NOTE: if there is a history of prior malignancy, patients must not be
receiving other specific treatment (chemotherapy, hormonal therapy, radiation) for
their cancer

- Not willing to discontinue use of supplemental vitamin E
We found this trial at
11
sites
Washington, District of Columbia 20007
Principal Investigator: Kenneth D. Burman
Phone: 202-877-2749
?
mi
from
Washington,
Click here to add this to my saved trials
12605 East 16th Avenue
Aurora, Colorado 80045
720-848-0000
Principal Investigator: Bryan R. Haugen
Phone: 720-848-0676
University of Colorado Hospital, Site Top medical professionals, superior medicine and progressive change make University...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Lori J. Wirth
Phone: 617-643-1751
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Columbus, Ohio 43210
Principal Investigator: Jennifer A. Sipos
Phone: 614-292-4511
?
mi
from
Columbus, OH
Click here to add this to my saved trials
2301 Erwin Rd
Durham, North Carolina 27710
919-684-8111
Principal Investigator: Julie A. Sosa
Phone: 919-684-8239
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
?
mi
from
Durham, NC
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Ramona Dadu
Phone: 713-792-0839
?
mi
from
Houston, TX
Click here to add this to my saved trials
3855 Health Sciences Dr,
La Jolla, California 92093
(858) 822-6100
Principal Investigator: Gregory A. Daniels
Phone: 858-822-5223
UC San Diego Moores Cancer Center Established in 1978, UC San Diego Moores Cancer Center...
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
Nashville, Tennessee 37232
Principal Investigator: Jill Gilbert
Phone: 615-875-2362
?
mi
from
Nashville, TN
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Principal Investigator: Alan L. Ho
Phone: 646-888-4450
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
Newport Beach, California 92663
Principal Investigator: Michael J. Demeure
Phone: 919-764-6586
?
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Rochester, Minnesota 55905
Principal Investigator: Mabel Ryder
Phone: 855-776-0015
?
mi
from
Rochester, MN
Click here to add this to my saved trials